Abstract

Adiponectin is an adipocytes-produced protein and showing a number of antiatherogenic effects. Adiponectin seems to be extensively deposited in the intersticium of venous lesions of persons with myocardial infarction. It may exhibit antiatherogenic and reparative effects. A decreased adiponectin concentration may be a risk factor of the origin and complications of atherosclerosis. 1) Do the adiponectin concentrations in venous blood of persons with acute coronary syndrome (ACS) differ from those in persons with stress angina pectoris? 2) In these persons do adiponectin concentrations in venous blood differ from those in main coronary arteries? 3) Do adiponectin levels differ in the infarction and non-infarction arteries in persons with STEMI (ST Elevation Myocardial Infarct) and delay within 4 hours after the onset? 4) In persons with ACS does any correlation exist between venous adiponectin and common risk factors of cardiovascular complications? Adiponectin concentration was determined in samples of blood collected from the peripheral vein and during coronarography in various localizations in 4 groups of examined persons (I. - no signs of CAD, II. - stable stress angina pectoris, III. - ACS over 48 hours without elevations of ST segment, IV. - STEMI during first 4 hours after its origin and proved occlusion of coronary artery at coronarography). Coronary angiography, risk factors and anamnestic data were analyzed. The software Medcalc was used to perform statistical analysis. We examined 73 probands with signs of myocardial ischemia (mean age of 61.5 years, 64 % males), who were subjected to coronarography and 21 healthy volunteers. A mean delay (delay from the origin of complaints to the performed coronarography) was 3.1 +/- 0.5 hours in individuals in the group IV. In patients with ACS we found lower adiponectin concentrations in venous blood compared to healthy individuals and persons with stress AP, but changes were not statistically significant (I.: -5.9 +/- 2.7 ng/l, II.: -4.9 +/- 1.2 ng/l, III.: -5.2 +/- 4.1 ng/l, IV.: -4.6 +/- 2.7 ng/l); no differences were found also with BMI. No significant difference was recorded between the samples of venous blood and those of coronary arteries, nor between the infarction and the non-infarction arteries in the group IV. (5.2 +/- 2.6 ng/l vs. 4.8 +/- -2.7 ng/l). Significant negative correlations were observed between adiponectin concentrations and BMI (correlation coefficient -0.29), triacylglycerols (correlation coefficient -0.4), AOPP (correlation coefficient -0.39), and positive correlations with HDL (correlation coefficient 0.32). No correlation was recorded between adiponectin and CRP. Adiponectin concentrations in persons with ACS are lower than in healthy persons or patients with stable angina pectoris, but differences are not statistically significant. The absence of adiponectin differences between the infarction/non-infarction artery may support the hypothesis of adiponectin uptake in the ischemic lesion with subsequent decrease in blood adiponectin. On the contrary, adiponectin decrease may be a risk factor independent of the origin and development of ACS.

Highlights

  • Adiponectin is an adipocytokin with numerous antiatherogenic properties

  • Referring to several recent papers reporting that adiponectin is localized in the interstice of infarction lesions and considerably affects expression of adhesive molecules production of growth factors and cytokines displaying the anthiatherogenic effect, we decided to aswer the following questions: – Does adiponectin concentration differ in persons with acute coronary syndrome from that in patients with stable angina pectoris and from healthy individuals? – Does adiponectin concentration in venous blood differ from that in main coronary arteries?

  • It was found that adiponectin concentrations in peripheral venous blood and arterial blood did not differ significantly and showed a significant correlation (Table 3)

Read more

Summary

Introduction

Adiponectin is an adipocytokin with numerous antiatherogenic properties. Its antiatherogenic effect is mediated through its binding ability to collagen (is accumulated in damaged arteries and has a potential antiatherogennic effect).Referring to several recent papers reporting that adiponectin is localized in the interstice of infarction lesions and considerably affects (decreases) expression of adhesive molecules production of growth factors and cytokines displaying the anthiatherogenic effect, we decided to aswer the following questions: – Does adiponectin concentration differ in persons with acute coronary syndrome from that in patients with stable angina pectoris and from healthy individuals? – Does adiponectin concentration in venous blood differ from that in main coronary arteries?D. Adiponectin is an adipocytokin with numerous antiatherogenic properties. Its antiatherogenic effect is mediated through its binding ability to collagen (is accumulated in damaged arteries and has a potential antiatherogennic effect). Referring to several recent papers reporting that adiponectin is localized in the interstice of infarction lesions and considerably affects (decreases) expression of adhesive molecules production of growth factors and cytokines displaying the anthiatherogenic effect, we decided to aswer the following questions: – Does adiponectin concentration differ in persons with acute coronary syndrome from that in patients with stable angina pectoris and from healthy individuals? – Does adiponectin concentration in venous blood differ from that in main coronary arteries?. – Does adiponectin concentration in persons with acute myocardial infarction differ in the infarction and the non-infarction artery?. – Does any correlation exist between adiponectin and common risk factors of cardiovascular complications?

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.